OCT 26, 2015 08:02 AM PDT

New Immunosuppressant Drug For Autoimmune Blood Diseases Undergoing Clinical Trials

WRITTEN BY: Kara Marker
Sirolimus, an immunosuppressant drug, as recently been used in clinical trials for patients with autoimmune blood disorders. Patients benefitting from sirolumus are highly resistant or intolerant to normal corticosteroid immunosuppressive therapy. Autoimmune lymphoproliferative syndrome (ALPS) is particularly responsive to experimental sirolimus treatments. This disease is extremely rare; only 200 ALPS patients have been identified worldwide (NIH). 

ALPS is a genetic disease that inhibits the body from producing the healthy amount of lymphoctes, resulting in a chronically swollen liver, spleen, and lymph nodes (NIH). ALPS and other autoimmune blood disorders can cause anemia, uncontrolled bleeding, and infection as the immune system targets healthy hematocytes (blood cells). 
A PET scan of an ALPS patient
Corticosteroids were discovered in the 1940s and are used often for regulating inflammation in autoimmune diseases. Unfortunately, their anti-inflammatory abilities are not without long-term adverse side effects. A 2011 review in Molecular and Cellular Endocrinology described corticosteroid treatment "clinical efficacy" as "compromised by the metabolic effects of long-treatment," including osteoporosis, hypertension, and type 2 diabetes. 

To bypass these unfavorable side effects as well as provide an option for ALPS patients resistant/intolerant to corticosteroids, scientists from the Children's Hospital of Philadelphia ran a clinical trial of 30 patients between 5 and 19 years old to see how sirolimus could be used to treat ALPS. 

Sirolimus has traditionally been prescribed to prevent the rejection of kidney transplants by suppressing the immune system (MedlinePlus). ALPS patients in the clinical trial received six months of sirolimus treatment, and there was large success with participants reaching normal blood cell counts. Patients also received a check-up after two years, and there were very few recorded adverse side effects. In addition, these patients were able to stop all other steroid treatments and rely on sirolimus to keep their disease in check. 

Senior study author David Teachey, MD, looks to sirolimus as a way for young ALPS patients to achieve "an improved quality of life as they continue treatment into adulthood."

In 2012, the Children's Hospital Boston also did a sirolumus clinical trail. Riley Cerabona, a child with CLOVES syndrome, participated in the trial. CLOVES (Congenital, Lipomatous, Overgrowth, Vascular Malformations, Epidermal Nevus, Scoliosis) is very rare (ClovesSyndrome.org). Watch the video below to hear her story and more about the potential of sirolimus as an immunosuppressant. 



Source: EurekAlert

 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
JUL 25, 2018
Immunology
JUL 25, 2018
T Cell Response to Ebola Virus Proteins
Killer T cells of Ebola survivors respond better to nucleoproteins, not glycoproteins, potentially influencing Ebola vaccine development....
JUL 31, 2018
Immunology
JUL 31, 2018
The Immune Systems Molecular Alphabet
Lab-designed nucleic acid nanoparticles elicit varied and specific immune response from immune cells based on shape, size, and formulation of each particle....
AUG 24, 2018
Cell & Molecular Biology
AUG 24, 2018
Chronic Allergies can Change Cells
Chronic rhinosinusitis is different from allergies; it leads to serious inflammation and swelling in the sinuses that can last for years....
SEP 25, 2018
Videos
SEP 25, 2018
Heal Faster
Active patient vs passive patient...
OCT 04, 2018
Videos
OCT 04, 2018
Why Do We Have Nightmares With a Fever?
Fever is the body’s response to a threat. When some viruses or bacteria try to enter the body, an immune response begins that can include a sharp ris...
OCT 09, 2018
Drug Discovery
OCT 09, 2018
'Copper Antibiotic Peptide' Effective in Eradicating Tuberculosis
The bacterium responsible for Tuberculosis has found a way to avoid antibiotics by hiding inside the macrophages which are the specific immune cells that a...
Loading Comments...